DA32 Life Science Tech Acquisition Corp.
| IPO Proceeds, $M | $200.00M |
|---|---|
| IPO Date | Jul 28, 2021 |
| CEO | Steve Kafka |
| Left Lead | JP Morgan |
| IPO Cash in Trust | 100.0% |
| SPAC Tenor | 24 months |
| IPO Sector |
Healthcare
Life sciences |
| IPO Geography | Global |
| Target Company | N/A |
| Deal Announced | N/A |
| Deal Size, $M | TBD |
| Deal Sector | TBD |
| Deal Geography | TBD |
| SEC Filings | www.sec.gov |
| Approval Vote | TBD |
| Amendment Vote | TBD |
| Closing Date | Jul 31, 2023 |
| Price | |
|---|---|
| Volume, 3-month avg. | N/A |
No credit card required
Sign in for more on DA32 Life Science Tech Acquisition Corp.:
- Structure and cap table
- 8 directors & officers
- 5 filings and events
- 2 underwriters
Structure
Sign in to view structure, cap table, and calendar of events.
Team
| Name | Age | Title |
|---|---|---|
| Steve Kafka | 51 | Chief Executive Officer and Director |
| Christopher Wolfe | 41 | Chief Financial Officer and Secretary |
| Andrew ElBardissi | 39 | Director |
| Keith Crandell | 61 | Director |
| Mara Aspinall | 58 | Director |
| Kevin Hrusovsky | 60 | Director |
| Angela Lai | 50 | Director |
| Nick Roelofs | 63 | Director |
Sign in to view team biographies and more sponsor and affiliate data.
Advisors
Filings
| Jul 2, 2021 | Initial S-1 |
| Jul 27, 2021 |
PR announcing pricing of $200mm IPO
Sign In to view filing content. |
| Jul 29, 2021 | 424B4 IPO Prospectus |
| Jul 21, 2023 |
8-K announcing liquidation and redemption of all public shares
Sign In to view filing content. |
| Jul 27, 2023 |
CA Corporate Action Alert with redemption rate and liquidation timeline
Sign In to view filing content. |